Advisory Committee on Immunization Practices (ACIP), 60877 [2013-24068]
Download as PDF
Federal Register / Vol. 78, No. 191 / Wednesday, October 2, 2013 / Notices
60877
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Centers for Disease Control and
Prevention
Centers for Disease Control and
Prevention
Disease, Disability, and Injury
Prevention and Control Special
Emphasis Panel (SEP): Initial Review
Advisory Committee on Immunization
Practices (ACIP)
Elaine L. Baker,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
The meeting announced below
concerns Occupational Safety and
Health Training Project Grants (T03),
PAR–10–288, initial review.
In accordance with Section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC)
announces the aforementioned meeting:
Time and Date: 8 a.m.–5 p.m.,
November 6, 2013 (Closed).
Place: Centers for Disease Control and
Prevention, Roybal Campus, Building
19–GCC, 1600 Clifton Road, Atlanta,
Georgia 30333, Telephone: (404) 639–
6000.
Status: The meeting will be closed to
the public in accordance with
provisions set forth in Section 552b(c)
(4) and (6), Title 5 U.S.C., and the
Determination of the Director,
Management Analysis and Services
Office, CDC, pursuant to Public Law 92–
463.
Matters To Be Discussed: The meeting
will include the initial review,
discussion, and evaluation of
applications received in response to
‘‘Occupational Safety and Health
Training Project Grants (T03) PAR–10–
288.’’
Joan
F. Karr, Ph.D., Scientific Review Officer,
CDC/NIOSH 1600 Clifton Road,
Mailstop E–74, Atlanta, Georgia 30333,
Telephone: (404) 498–2506.
The Director, Management Analysis
and Services Office, has been delegated
the authority to sign Federal Register
notices pertaining to announcements of
meetings and other committee
management activities, for both the
Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
tkelley on DSK3SPTVN1PROD with NOTICES
FOR FURTHER INFORMATION CONTACT:
Elaine L. Baker,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
[FR Doc. 2013–24065 Filed 10–1–13; 8:45 am]
BILLING CODE 4163–18–P
VerDate Mar<15>2010
17:48 Oct 01, 2013
Jkt 232001
In accordance with section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC) announce
the following meeting of the
aforementioned committee:
Times and Dates:
8:00 a.m.–5:45 p.m., October 23, 2013.
8:00 a.m.–1:00 p.m., October 24, 2013.
Place: CDC, Tom Harkin Global
Communications Center, 1600 Clifton Road
NE., Building 19, Kent ‘‘Oz’’ Nelson
Auditorium, Atlanta, Georgia 30333.
Status: Open to the public, limited only by
the space available. Meeting is webcast live
via the World Wide Web; for instructions and
more information on ACIP please visit the
ACIP Web site: https://www.cdc.gov/vaccines/
acip/.
Purpose: The committee is charged with
advising the Director, CDC, on the
appropriate uses of immunizing agents. In
addition, under 42 U.S.C. 1396s, the
committee is mandated to establish and
periodically review and, as appropriate,
revise the list of vaccines for administration
to vaccine-eligible children through the
Vaccines for Children (VFC) program, along
with schedules regarding the appropriate
periodicity, dosage, and contraindications
applicable to the vaccines. Further, under
provisions of the Affordable Care Act, at
section 2713 of the Public Health Service
Act, immunization recommendations of the
ACIP that have been adopted by the Director
of the Centers for Disease Control and
Prevention must be covered by applicable
health plans.
Matters To Be Discussed: The agenda will
include discussions on: child/adolescent
immunization schedule, adult immunization
schedule, meningococcal vaccines,
pneumococcal conjugate vaccine, herpes
zoster vaccine, tetanus, diphtheria and
acellular pertussis vaccine, yellow fever
vaccine, global immunization update, human
papillomavirus vaccines, general
recommendations on immunizations, and
influenza. Recommendation votes are
scheduled for child/adolescent immunization
schedule, adult immunization schedule, and
meningococcal vaccines. Time will be
available for public comment.
Agenda items are subject to change as
priorities dictate.
Contact Person For More Information:
Felicia Betancourt, National Center for
Immunization and Respiratory Diseases,
CDC, 1600 Clifton Road NE., MS–A27,
Atlanta, Georgia 30333, telephone 404/639–
8836; Email ACIP@CDC.GOV.
The Director, Management Analysis and
Services Office, has been delegated the
authority to sign Federal Register notices
pertaining to announcements of meetings and
other committee management activities, for
PO 00000
Frm 00062
Fmt 4703
Sfmt 4703
[FR Doc. 2013–24068 Filed 10–1–13; 8:45 am]
BILLING CODE 4160–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Advisory Committee on Immunization
Practices (ACIP)
In accordance with section 10(a) (2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC) announce
the following meeting of the
aforementioned committee:
Times and Dates: 8 a.m.–5:45 p.m.,
October 23, 2013; 8 a.m.–1 p.m., October 24,
2013.
Place: CDC, Tom Harkin Global
Communications Center, 1600 Clifton Road
NE., Building 19, Kent ‘‘Oz’’ Nelson
Auditorium, Atlanta, Georgia 30333.
Status: Open to the public, limited only by
the space available. Meeting is Webcast live
via the World Wide Web; for instructions and
more information on ACIP please visit the
ACIP Web site: https://www.cdc.gov/vaccines/
acip/. Purpose: The committee is
charged with advising the Director, CDC, on
the appropriate uses of immunizing agents.
In addition, under 42 U.S.C. 1396s, the
committee is mandated to establish and
periodically review and, as appropriate,
revise the list of vaccines for administration
to vaccine-eligible children through the
Vaccines for Children (VFC) program, along
with schedules regarding the appropriate
periodicity, dosage, and contraindications
applicable to the vaccines. Further, under
provisions of the Affordable Care Act, at
section 2713 of the Public Health Service
Act, immunization recommendations of the
ACIP that have been adopted by the Director
of the Centers for Disease Control and
Prevention must be covered by applicable
health plans.
Matters To Be Discussed: The agenda will
include discussions on: child/adolescent
immunization schedule, adult immunization
schedule, meningococcal vaccines,
pneumococcal conjugate vaccine, herpes
zoster vaccine, tetanus, diphtheria and
acellular pertussis vaccine, yellow fever
vaccine, global immunization update, human
papillomavirus vaccines, general
recommendations on immunizations, and
influenza. Recommendation votes are
scheduled for child/adolescent immunization
schedule, adult immunization schedule, and
meningococcal vaccines. Time will be
available for public comment. Agenda items
are subject to change as priorities dictate.
E:\FR\FM\02OCN1.SGM
02OCN1
Agencies
[Federal Register Volume 78, Number 191 (Wednesday, October 2, 2013)]
[Notices]
[Page 60877]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-24068]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Advisory Committee on Immunization Practices (ACIP)
In accordance with section 10(a)(2) of the Federal Advisory
Committee Act (Pub. L. 92-463), the Centers for Disease Control and
Prevention (CDC) announce the following meeting of the aforementioned
committee:
Times and Dates:
8:00 a.m.-5:45 p.m., October 23, 2013.
8:00 a.m.-1:00 p.m., October 24, 2013.
Place: CDC, Tom Harkin Global Communications Center, 1600
Clifton Road NE., Building 19, Kent ``Oz'' Nelson Auditorium,
Atlanta, Georgia 30333.
Status: Open to the public, limited only by the space available.
Meeting is webcast live via the World Wide Web; for instructions and
more information on ACIP please visit the ACIP Web site: https://www.cdc.gov/vaccines/acip/.
Purpose: The committee is charged with advising the Director,
CDC, on the appropriate uses of immunizing agents. In addition,
under 42 U.S.C. 1396s, the committee is mandated to establish and
periodically review and, as appropriate, revise the list of vaccines
for administration to vaccine-eligible children through the Vaccines
for Children (VFC) program, along with schedules regarding the
appropriate periodicity, dosage, and contraindications applicable to
the vaccines. Further, under provisions of the Affordable Care Act,
at section 2713 of the Public Health Service Act, immunization
recommendations of the ACIP that have been adopted by the Director
of the Centers for Disease Control and Prevention must be covered by
applicable health plans.
Matters To Be Discussed: The agenda will include discussions on:
child/adolescent immunization schedule, adult immunization schedule,
meningococcal vaccines, pneumococcal conjugate vaccine, herpes
zoster vaccine, tetanus, diphtheria and acellular pertussis vaccine,
yellow fever vaccine, global immunization update, human
papillomavirus vaccines, general recommendations on immunizations,
and influenza. Recommendation votes are scheduled for child/
adolescent immunization schedule, adult immunization schedule, and
meningococcal vaccines. Time will be available for public comment.
Agenda items are subject to change as priorities dictate.
Contact Person For More Information: Felicia Betancourt,
National Center for Immunization and Respiratory Diseases, CDC, 1600
Clifton Road NE., MS-A27, Atlanta, Georgia 30333, telephone 404/639-
8836; Email ACIP@CDC.GOV.
The Director, Management Analysis and Services Office, has been
delegated the authority to sign Federal Register notices pertaining
to announcements of meetings and other committee management
activities, for both the Centers for Disease Control and Prevention
and the Agency for Toxic Substances and Disease Registry.
Elaine L. Baker,
Director, Management Analysis and Services Office, Centers for Disease
Control and Prevention.
[FR Doc. 2013-24068 Filed 10-1-13; 8:45 am]
BILLING CODE 4160-18-P